日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

m(6)A-Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism

m(6)A修饰的circRAPGEF1与IGF2BP3的相互作用通过重编程天冬氨酸代谢促进肝细胞癌进展

Shi, Juanyi; Mui, Sintim; Yan, Yongcong; Liu, Shaomin; Wen, Kai; He, Chuanchao; Li, Huoming; Liao, Hao; Tao, Meng; Wen, Jiahua; Wang, Weidong; Xu, Xiaoding; Zhou, Zhenyu; Xiao, Zhiyu

A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study

基于深度学习的临床放射组学模型预测潜在可转化肝细胞癌患者对免疫检查点抑制剂(ICIs)转化疗法的治疗反应:一项肿瘤标志物预后研究

Lin, Zijian; Wang, Weidong; Yan, Yongcong; Ma, Zifeng; Xiao, Zhiyu; Mao, Kai

Integrated analysis reveals an immune evasion prognostic signature for predicting the overall survival in patients with hepatocellular carcinoma

综合分析揭示了一种免疫逃逸预后特征,可用于预测肝细胞癌患者的总生存期

Wen, Jiahua; Wen, Kai; Tao, Meng; Zhou, Zhenyu; He, Xing; Wang, Weidong; Huang, Zian; Lin, Qiaohong; Li, Huoming; Liu, Haohan; Yan, Yongcong; Xiao, Zhiyu

A radiomic model for noninvasive prediction of PD-L1 and VETC expression in hepatocellular carcinoma using enhanced abdominal CT

利用增强腹部CT对肝细胞癌中PD-L1和VETC表达进行无创预测的放射组学模型

Wang, Weidong; Lu, Junrong; Yan, Yongcong; Wen, Kai; Guo, Gefan; Zhou, Zhenyu; Xiao, Zhiyu

Multi-omics analysis identifies OSGEPL1 as an oncogene in hepatocellular carcinoma.

多组学分析表明 OSGEPL1 是肝细胞癌中的一种癌基因

Mui Sintim, Shi Juanyi, Wen Kai, Yan Yongcong, Li Huoming, Wang Weidong, Zhou Zhenyu, Xiao Zhiyu

Fluorescence-guided laparoscopic resection of liver segment 4 plus the right anterior ventral section for hepatocellular carcinoma adjacent to the left hepatic pedicle and middle hepatic vein: a case report

荧光引导下腹腔镜切除肝段4及右前腹侧部分治疗邻近左肝蒂及肝中静脉的肝细胞癌:病例报告

Huang, Zian; Yan, Yongcong; Chen, Yajin; Stavrou, Gregor Alexander; Xiao, Zhiyu; Zhou, Zhenyu

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

乐伐替尼在晚期肝细胞癌患者中的应用及耐药机制

Tao, Meng; Han, Jing; Shi, Juanyi; Liao, Hao; Wen, Kai; Wang, Weidong; Mui, Sintim; Li, Huoming; Yan, Yongcong; Xiao, Zhiyu

Prognostic nomogram for predicting cancer-specific survival in patients with resected hilar cholangiocarcinoma: a large cohort study

用于预测切除肝门部胆管癌患者癌症特异性生存率的预后列线图:一项大型队列研究

Yu, Zhimin; Liu, Qinghua; Liao, Hao; Shi, Juanyi; Zhou, Zhenyu; Yan, Yongcong; Xu, Junyao; He, Chuanchao; Mao, Kai; Zhang, Jianlong; Wang, Jie; Xiao, Zhiyu

SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters

SMYD3通过甲基化S1PR1启动子促进肝细胞癌进展

Zhang, Heyun; Zheng, Zhangyu; Zhang, Rongqin; Yan, Yongcong; Peng, Yaorong; Ye, Hua; Lin, Lehang; Xu, Junyao; Li, Wenbin; Huang, Pinbo

Correction: SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters

更正:SMYD3 通过甲基化 S1PR1 启动子促进肝细胞癌进展

Zhang, Heyun; Zheng, Zhangyu; Zhang, Rongqin; Yan, Yongcong; Peng, Yaorong; Ye, Hua; Lin, Lehang; Xu, Junyao; Li, Wenbin; Huang, Pinbo